Ella A. Eklund
Goeteborg, O 41345, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
ICMT supports BRAFV600E-driven tumor growth by membrane targeting of the CAAX protein INPP5E.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 13, 2026
BRAF inhibition increases TGFβ2 production and stimulates metastasis in mice with endogenous BRAFV600E-induced hepatocellular carcinoma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 06, 2025
Brain metastasis in stage IV lung adenocarcinoma is frequently missed by symptom-based screening.
Journal: Discover oncology
Published: June 11, 2025
Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish Cohort.
Journal: JTO clinical and research reports
Published: April 09, 2025
High baseline PD-1+ CD8 T Cells and TIGIT+ CD8 T Cells in circulation associated with response to PD-1 blockade in patients with non-small cell lung cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: March 17, 2025
Distinct metastatic organotropism shapes prognosis in lung adenocarcinoma with brain metastasis.
Journal: Frontiers in oncology
Published: January 31, 2025
Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: December 22, 2024
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 05, 2024
Ageing promotes metastasis via activation of the integrated stress response.
Journal: Nature
Published: June 20, 2024
Assessing the prognostic value of KRAS mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysis.
Journal: Frontiers in oncology
Published: March 05, 2024
Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less KRAS and More EGFR Mutations Compared to Advanced Adenocarcinomas.
Journal: International journal of molecular sciences
Published: January 08, 2024
Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer.
Journal: Frontiers in oncology
Published: October 18, 2022
Last Updated: 09/26/2026